Patching adherence is linked to improved grating visual acuity

Article

Patching during the first six months after surgery is linked to improved grating visual acuity in infants with unilateral cataract.

Patching during the first six months after surgery is linked to improved grating visual acuity in infants with unilateral cataract, reveals a paper in Investigative Ophthalmology & Visual Science.

Dr Carolyn D. Drews-Botsch et al., Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, completed a randomized clinical trial of 108 infants with unilateral congenital cataract.

Patching was conducted one hour per day every month until the patient was eight months of age. The mean percentage of prescribed patching was used to measure adherence in a weeklong diary completed two months postoperatively. Recall interviews lasting 48 hours were also performed three and six months postoperatively.

Teller Acuity Cards were used to measure grating visual acuity within one month of the infant's first birthday. The link between grating acuity and patching was found with nonparametric correlations.

The results revealed that 84.3% of prescribed time and adherence did not change according to treatment. Adherence was found to be strongly associated with grating acuity, especially among pseudophakic patients compared to aphakic infants. Implanting an intraocular lens (IOL) was not linked to adherence.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.